{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:11:07Z","timestamp":1780535467990,"version":"3.54.1"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T00:00:00Z","timestamp":1181001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To compare the clinical and bacteriological efficacy and the clinical safety of a 1\u2010day with a 3\u2010day regimen of an extended\u2010release formulation of ciprofloxacin (ciprofloxacin XR) given as antimicrobial prophylaxis to men undergoing transrectal needle biopsy of the prostate (TRNBP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>This was a multicentre, prospective, international, double\u2010blind study in patients who required TRNBP. Patients were randomized to receive oral ciprofloxacin XR 1000\u2003mg as either a 1\u2010day or a 3\u2010day regimen. Single doses were given at 24\u2003h before, 2\u20133\u2003h before, and 24\u2003h after TRNBP. Patients in the 1\u2010day regimen had placebo instead of the first and third doses of ciprofloxacin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of 497 patients enrolled, 247 were randomized to 1\u2010day ciprofloxacin XR and 250 to the 3\u2010day regimen. In the population valid for microbiological efficacy, the final assessment identified bacteriological success (primary efficacy endpoint) in more patients who had the 3\u2010day regimen (98%) than in those who received the 1\u2010day regimen (94.8%, 95% confidence interval, CI, \u2212\u200a6.1%, 0.8%), although the difference was not statistically significant. In this population, the clinical response at the final visit was 98.5% and 96.7% for patients receiving the 3\u2010day and the 1\u2010day regimens, respectively (95% CI \u2212\u200a5.2%, 0.8%). However, in the clinical efficacy population the clinical success rate was significantly greater for the 3\u2010day (99.0%) than for the 1\u2010day regimen (95.8%; 95% CI \u2212\u200a6.4%, \u2212\u200a0.3%). In a multivariate analysis, patients with diabetes mellitus and patients with a history of prostatitis had higher microbiological and clinical failure rates, respectively, than those without such conditions. For these patients, all failures occurred among those treated with the 1\u2010day regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>As defined by bacteriological success in the population assessed for microbiological efficacy, prophylaxis with one dose of ciprofloxacin XR was statistically no worse than a 3\u2010day regimen. However, in all efficacy analyses, bacteriological and clinical success rates were consistently lower for the 1\u2010day than for the 3\u2010day treatment. Thus, for selected patients undergoing TRNBP, there might be a role for 3\u2010day preventive therapy with ciprofloxacin XR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2007.06848.x","type":"journal-article","created":{"date-parts":[[2007,6,6]],"date-time":"2007-06-06T00:59:06Z","timestamp":1181091546000},"page":"51-57","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Comparison of a 3\u2010day with a 1\u2010day regimen of an extended\u2010release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate"],"prefix":"10.1111","volume":"100","author":[{"given":"Anthony J.","family":"Schaeffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Scattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Perroncel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Haverstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Pertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,6,5]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01958-1"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-7709"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800670217"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2002.02735.x"},{"key":"e_1_2_8_6_2","first-page":"75","article-title":"Antimicrobial prophylaxis in surgery","volume":"41","author":"No authors listed.","year":"1999","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)69087-6"},{"key":"e_1_2_8_8_2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1742-1241.2003.tb10612.x","article-title":"A national survey of transrectal ultrasound\u2010guided prostatic biopsies: time for a national guideline","volume":"57","author":"Patel HR","year":"2003","journal-title":"Int J Clin Pract"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00313-6"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-005-0076-2"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1982.tb13637.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(97)80161-4"},{"key":"e_1_2_8_13_2","first-page":"1066","article-title":"Prostate needle biopsy infection after four or six dose ciprofloxacin","volume":"7","author":"Janoff DM","year":"2000","journal-title":"Can J Urol"},{"key":"e_1_2_8_14_2","first-page":"2216","article-title":"A prospective randomized trial of 1\u2010day versus 3\u2010day antibiotic prophylaxis for transrectal ultrasound guided prostate biopsy","volume":"11","author":"Sabbagh R","year":"2004","journal-title":"Can J Urol"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2000.00576.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-55382003000400005"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1996.01014.x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)64716-5"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)53860-4"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)57246-8"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.138.3.393"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/9781555817817.Ch5"},{"key":"e_1_2_8_23_2","volume-title":"Categorical Data Analysis","author":"Agresti A","year":"1990"},{"key":"e_1_2_8_24_2","first-page":"1203","article-title":"Ciprofloxacin pharmacokinetics (PK) in prostate tissue following a single 1000 mg oral ciprofloxacin extended release tablet (Cipro XR)","volume":"44","author":"Childs S","year":"2004","journal-title":"J Clin Pharmacol"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2007.06848.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2007.06848.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:52:23Z","timestamp":1761760343000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2007.06848.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,5]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1111\/j.1464-410X.2007.06848.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2007.06848.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,5]]},"assertion":[{"value":"2007-06-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}